Tumor necrosis factor: how to improve the antitumor activity and decrease accompanying side effects for therapeutic application.
Haranaka
K
K
Department of Internal Medicine, University of Tokyo, Japan.
D000818:Animals; D000970:Antineoplastic Agents; D002986:Clinical Trials as Topic; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D015227:Lipid Peroxidation / Q000187:drug effects; D008247:Lysosomes / Q000201:enzymology; D008954:Models, Biological; D010100:Oxygen / Q000502:physiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D010100:Oxygen